Ask AI
ProCE Banner Series

The Next Frontier for CDK4/6 Inhibitors in Breast Cancer: Expert Strategies for Applying the Latest Guidelines and Advances in Practice

Join us for this engaging session led by expert oncology faculty to learn the latest evidence and recommendations with the CDK4/6 inhibitors for early and advanced breast cancer, along with their insights on optimizing CDK4/6 inhibitor–related adverse event mitigation and management.

Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

  AAPA
  | ACPE
  | AMA
  | ANCC with Pharmacotherapy Credit
Who Should Attend

This activity is intended for oncologists, physician associates, nurse practitioners, nurses, pharmacists, and other healthcare professionals who care for patients with breast cancer.

All Events

The Next Frontier for CDK4/6 Inhibitors in Breast Cancer: Expert Strategies for Applying the Latest Guidelines and Advances in Practice

Upcoming Events

May

30

2026

6:30 PM - 8:30 PM Central Time (CT)

In-person

Hilton Chicago, 720 S Michigan Ave., Chicago, Illinois 60625

7:00 PM - 8:30 PM Central Time (CT)

Virtual

Topics

Breast cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve learners’ knowledge, competence, and confidence to integrate CDK4/6 inhibitors into practice to improve clinical outcomes in appropriate patients with early and metastatic breast cancer.

Target Audience
This activity is intended for oncologists, physician associates, nurse practitioners, nurses, pharmacists, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate current CDK4/6 inhibitor therapies into treatment plans of appropriate patients with HR+/HER2- early breast cancer in alignment with NCCN Guidelines and expert-recommended best practices

  • Align current CDK4/6 inhibitor treatment in patients with HR+/HER2- metastatic breast cancer with NCCN Guidelines and expert-recommended best practices

  • Manage adverse events associated with CDK4/6 inhibitors to foster and optimize treatment adherence, persistence, and enhance overall outcomes of patients with breast cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

NCCN designates this educational activity for a maximum of 1.5 contact hours. This program offers 1.5 pharmacotherapeutic contact hours for nurses. 

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-26-039-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

For ABIM MOC points, your information will be shared with the ABIM through NCCN’s Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

Disclosure of Conflicts of Interest
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 

Acknowledgement

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Decera Clinical Education.

NCCN

Supporters

Supported by educational grants from Lilly and Novartis.

Lilly

Novartis

Partners

Decera Clinical Education

ProCE Banner

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191